BRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Reuters

25 Apr

BRIEF-<a href="https://laohu8.com/S/CRBU">Caribou Biosciences</a> Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

April 24 (Reuters) - Caribou Biosciences Inc CRBU.O:

CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMS
CARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32%
CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUS
CARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AML
CARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027
CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025

Source text: ID:nGNXbzM3y0

Further company coverage: CRBU.O

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2530799463"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530799463\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2530799463?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530799463","market":"us","top_or_hot":-1,"title":"BRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs</title></head><body><p><span>April 24 (Reuters)</span><span> - </span>Caribou Biosciences Inc <span>CRBU.O</span>:</p><ul><li><p>CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMS</p></li><li><p>CARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32%</p></li><li><p>CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUS</p></li><li><p>CARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AML</p></li><li><p>CARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027</p></li><li><p>CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025</p></li></ul><p>Source text: <span>ID:nGNXbzM3y0</span></p><p>Further company coverage: <span>CRBU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-25 05:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs</title></head><body><p><span>April 24 (Reuters)</span><span> - </span>Caribou Biosciences Inc <span>CRBU.O</span>:</p><ul><li><p>CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMS</p></li><li><p>CARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32%</p></li><li><p>CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUS</p></li><li><p>CARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AML</p></li><li><p>CARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027</p></li><li><p>CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025</p></li></ul><p>Source text: <span>ID:nGNXbzM3y0</span></p><p>Further company coverage: <span>CRBU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R23HW:1","article_id":"2530799463","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530799463","pubTimestamp":1745531623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology ProgramsApril 24 (Reuters) - Caribou Biosciences Inc CRBU.O:CARIBOU BIOSCIENCES ANNOUNCES","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","CRBU":"Caribou Biosciences"},"translate_title":"简介-Caribou Biosciences宣布战略管道优先顺序，重点关注CB-010和CB-011肿瘤项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":0.9},"content_text":"BRIEF-Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology ProgramsApril 24 (Reuters) - Caribou Biosciences Inc CRBU.O:CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMSCARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32%CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUSCARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AMLCARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025Source text: ID:nGNXbzM3y0Further company coverage: CRBU.O ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}